Natural killer (NK) cells and NK cell activity were determined in three groups (newly diagnosed [n = 211, on therapy [n = 211, and off therapy [n = 181) of children with various types of malignant solid tumors and in a control group (n = 26) by means of Leu-7 and Leu-llb monoclonal antibodies and a
Natural killer cell function in children with malignant solid neoplasias
✍ Scribed by Gallego-Melcón, Soledad ;Boren, Teresa Español ;de Toledo, Jose Sanchez ;Viñas, Jorge Prats
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 584 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Natural killer (NK) cell numbers and lytic activity were determined in 40 children with various types of solid malignant neoplasias and in 25 control children by NKH-1 monoclonal antibody and cytotoxicity against K562 target cells, respectively. Patients were analyzed at the time of diagnosis before initiation of therapy and followed over a median time of 15.8 months. Mean NK cell numbers and lytic activity were similar among different types of tumor analyzed. Patients with localized disease (stages I, II; n = 25) also showed values not statistically different from those of patients in advanced disease (stages III, IV; n = 15). According to their response to therapy, patients were divided into three groups: group 1 (complete remission; n = 28), group 2 (partial remission; n = 5), and group 3 (progression of disease; n = 6). Patients in group 3 showed at the time of diagnosis a mean NK activity significantly lower than that of patients in groups 1 and 2 and control children (P = 0.007). The defect in NK cell lytic capacity in vitro observed in patients with progressive disease suggests that NK cells play a role in the control of neoplastic growth in vivo and may imply that some children with refractory progressive disease can benefit from immunomodulation destined to improve the lytic potential of NK cells.
📜 SIMILAR VOLUMES
Lymphokine-activated killer activity and natural killer activity in hepatocellular carcinoma patients were d. Maximum lymphokine-activated killer activity was induced at 3 to 6 days of incubation, and lymphokine-activated killer activity tended to increase in a manner dose dependent of recombinant i